Results
type 2 diabetes, diabetes
TYPE 1 DIABETES, TYPE 2 DIABETES, DIABETES
A total of 226 participants with diabetes were recruited from outpatient clinics in the Netherlands and Spain, including 108 from Leiden University Medical Center and affiliating teaching hospitals (83 with type 1 diabetes; 25 with type 2 diabetes) and 118 from Reina Sofía University Hospital, Córdoba, Spain (25 with type 1 diabetes; 93 with type 2 diabetes). Of these, 111 were randomised to the POWER2DM group and 115 to the usual care group (Table Baseline characteristicsValues are means ± SD or Information about sex (female/male) was self-reported by participantsDPP-4, dipeptidylpeptidase-4; GLP-1, glucagon-like peptide-1; SGLT-2, sodium–glucose cotransporter-2Flow chart showing the number of study participants in each group and the number for whom HbAOverall, of the 226 participants included in the study, 108 had type 1 diabetes and 118 had type 2 diabetes (Table 